30 likes | 345 Views
BARI 2D. Mortality: 11.7% with revasc. vs. 12.2% with medical therapy; 11.8% with insulin-sensitization vs. 12.1% with insulin-provision PCI stratum, MACE: 23.0% with revasc. vs. 21.1% with medical therapy (p = 0.15)
E N D
BARI 2D Mortality: 11.7% with revasc. vs. 12.2% with medical therapy; 11.8% with insulin-sensitization vs. 12.1% with insulin-provision PCI stratum, MACE: 23.0% with revasc. vs. 21.1% with medical therapy (p = 0.15) CABG stratum, MACE: 22.4% with revasc. vs. 30.5% with medical therapy (p = 0.01) Trial design: Patients with type 2 diabetes and CAD were randomized (2 x 2 factorial design) to revascularization (n = 953) vs. medical therapy (n = 991) and to insulin-sensitization (n = 977) vs. insulin-provision (n = 967). Follow-up was 5.3 years. Results (p = 0.97) (p = 0.89) 12.1 12.2 11.8 11.7 % Conclusions • Among patients with diabetes and stable CAD, revascularization by PCI or CABG failed to demonstrate superiority to medical therapy at 5.3 years • There was no notable benefit from insulin-sensitizing therapy vs. insulin-providing therapy Mortality Mortality Insulin- sensitization Revascularization Medical therapy Insulin-provision BARI 2D Study Group. N Engl J Med 2009;360:2503-15